|
|
|
Volumn 5, Issue 2, 2003, Pages 192-198
|
|
Technology evaluation: Epratuzumab, Immunomedics/Amgen
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
EPRATUZUMAB;
IBRITUMOMAB TIUXETAN;
PENTETIC ACID;
RITUXIMAB;
YTTRIUM 90;
ANAPHYLAXIS;
ANTINEOPLASTIC ACTIVITY;
BURKITT LYMPHOMA;
CELL MEDIATED CYTOTOXICITY;
CLINICAL TRIAL;
DRUG BINDING;
DRUG CLEARANCE;
DRUG CONTRAINDICATION;
DRUG DISTRIBUTION;
DRUG HALF LIFE;
DRUG MECHANISM;
DRUG MEGADOSE;
DRUG METABOLISM;
DRUG SYNTHESIS;
HUMAN;
HYPERSENSITIVITY;
LYMPHOMA;
MOUSE;
NONHODGKIN LYMPHOMA;
NONHUMAN;
REVIEW;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
AUTOIMMUNE DISEASES;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
HUMANS;
LYMPHOMA;
|
|
EID: 0038814084
PISSN: 14648431
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (15)
|
|
References (0)
|
